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Abstract 
Purpose: The role of estrogen in cardiovascular health remains contested with discrepancies 
between findings from randomized controlled trials and observational studies. Mendelian 
randomization, which assesses the effect of lifelong endogenous exposure, may help elucidate 
these discrepancies.  
Methods: We used separate sample instrumental variable analysis to estimate the association of log 17β 
estradiol with factors related to cardiovascular disease risk (systolic and diastolic blood pressure, 
lipids, fasting glucose, body mass index, waist hip ratio, and waist circumference), and 
Framingham score, a predictor of 10-year risk of ischemic heart disease events, in older Chinese 
women from the Guangzhou Biobank Cohort Study (GBCS, n=3,092). The estimate was derived using 
the Wald estimator, i.e. the ratio of the association of genetic determinants (rs1008805 and rs2175898) of 
log 17β-estradiol with cardiovascular disease risk factors and Framingham score in GBCS and the 
association of these genetic determinants with log 17β-estradiol in a sample of young women from Hong 
Kong (n=236). 
Results: Genetically higher 17β-estradiol was not associated with any cardiovascular disease 
related risk factor, or with Framingham score(-0.01, 95% confidence interval -1.34 to 1.31).  
Conclusions: Lifetime exposure to estrogen does not appear to be cardio-protective via the 
cardiovascular disease related risk factors examined.  
 
 
 
Highlights 
• Mendelian randomization assesses lifelong exposure and is less prone to confounding 
• Mendelian randomization showed no effect of lifelong estrogen on CVD risk factors 
• Our study does not support the timing hypothesis as explanation for trial results 
• Discrepancies between observational studies and trials is likely due to confounding 
 
  
Introduction 
The role of estrogen in cardiovascular disease and its risk factors has been intensively 
investigated for many years. Initially it was thought that estrogen protects against cardiovascular 
disease because women have lower cardiovascular disease rates than men and the menopause 
precedes an increase in cardiovascular deaths. However, randomized controlled trials (RCTs) 
suggests that hormone replacement therapy (HRT) has little overall effect on cardiovascular 
disease or its risk factors but decreases LDL-cholesterol slightly (1), decreases diabetes and 
increases the risk of thrombosis and stroke (2). Nevertheless, findings from these RCTs have 
been contested (3), and the possibility that estrogens have some cardiovascular benefits remains 
a topic of active experimental investigation (4). First, some hormone replacement trials mainly 
used estrogen and progestin, whose effects may differ from estrogen alone (2). For example in 
the Women’s Health Initiative (WHI) trial, estrogen and progestin together may increase the risk 
of ischemic heart disease whereas estrogen only had no effect (2). Second, the effect of estrogen 
on cardiovascular risk may depend on other factors, such as timing of HRT initiation (4, 5) or the 
presence of atherosclerosis, i.e., when atherosclerosis is absent estrogen protects but when 
atherosclerosis is present estrogen is detrimental (6). Given the risk of breast cancer and venous 
thrombosis from estrogen administration, further major RCTs of estrogen are unlikely, but the 
role of estrogen in cardiovascular disease remains an important topic relevant to the widespread 
use of oral contraceptives including estrogen. In this situation replication, or otherwise, using a 
different approach can make a key contribution. In this study, for the first time, we used a 
separate sample Mendelian randomization analysis to assess the lifelong effect of estrogen on 
cardiovascular disease risk factors, overall and in women without cardiovascular disease.  
 
Mendelian randomization analysis, i.e., instrumental variable analysis with genetic instruments, 
is increasingly used to evaluate the causal role of risk factors in disease, particularly when RCTs 
are unavailable. Mendelian randomization may also enable assessment of the effects of 
endogenous rather than exogenous exposure, which may differ, because Mendelian 
randomization tests a causal pathway while an RCT tests an intervention which can have 
unknown pleiotropic effects (7). Genetic polymorphisms associated with the exposure are 
randomly allocated during conception, so this resembles the randomization process in RCTs and 
hence is less susceptible to confounding (8). Mendelian randomization analyses have clarified 
the role of many factors in cardiovascular disease etiology, such as C reactive protein (9). 
However, a conventional Mendelian randomization analysis is sensitive to measurement error of 
the exposure, which may lead to inflated estimates (10). Separate sample Mendelian 
randomization analysis, where a genetic prediction rule is generated in a sample less susceptible 
to measurement error, may alleviate this problem (11). We have successfully implemented this 
approach to examine the effect of testosterone on cardiovascular disease risk factors and of 
testosterone and estrogen on inflammation in older people (12-14). In this study, we examined 
the relation of lifelong exposure to estrogen with cardiovascular disease risk factors using a 
Mendelian randomization analysis among Southern Chinese women to clarify the role of lifelong 
estrogen exposure in health. 
 
Materials and methods 
 
Sources of data 
Two groups of women of different ages from the same genetic background, that is, from Hong 
Kong and Guangzhou, the capital of Guangdong, in Southern China, were recruited. Most Hong 
Kong residents are first, second or third generation migrants from Guangdong (15). First, 237 
young women (mean age 21.0 years) were recruited with restriction to those with both parents 
and at least three grandparents born in Hong Kong or Guangdong and not taking hormone-
related medication. Morning blood samples were taken on the 4th day to 7th day of the menstrual 
cycle for 17β-estradiol assessment, by immunoassay (Ortho Clinical Diagnostics Vitros Eci), and 
DNA extraction. Self-administered questionnaires were used to collect information, such as 
socioeconomic position and health status. Second, we used a sample of older women (50+ years) 
from GBCS, an ongoing collaboration of Guangzhou Number 12 Hospital, the Universities of 
Hong Kong and Birmingham, UK (16). Recruitment of participants was in 3 phases. All 
participants were permanent residents of Guangzhou and members of “The Guangzhou Health 
and Happiness Association for the Respectable Elders” (GHHARE), a community social and 
welfare association unofficially aligned with the municipal government. Membership is open to 
older people for a monthly fee of 4 Yuan (50 US cents). About 7% of permanent Guangzhou 
residents aged 50+ years are members of GHHARE, of whom 11% (about 10,000 participants) 
enrolled for each of phases one, two and three. The inclusion criteria were that they were capable 
of consenting, ambulatory, and not receiving treatment modalities which, if omitted, may result 
in immediate life-threatening risk, such as chemotherapy or radiotherapy for cancer, or dialysis 
for renal failure. The methods of measurement have previously been reported (16).  Standing 
height was measured without shoes to the nearest 0.1 centimetre. Weight was measured in light 
clothing to the nearest 0.1 kilogram. Hip circumference was measured at the greatest 
circumference round the buttocks below the iliac crest. Waist circumference was measured 
horizontally around the smallest circumference between the ribs and iliac crest, or at the level of 
the naval for obese participants. Body mass index (BMI) was calculated as the weight in 
kilograms divided by the square of height in meters. We recorded seated blood pressure as the 
average of the last two or three measurements, using the Omron 705CP sphygmomanometer 
(Omron Corp., Kyoto, Japan). Fasting low density lipoprotein (LDL) cholesterol, HDL 
cholesterol, triglyceride, and glucose levels were determined with a Shimadzu CL-8000 clinical 
chemical analyzer (Shimadzu Corp., Kyoto, Japan) in the hospital laboratory. Fasting blood 
samples were collected at recruitment in phase 3 or at follow up for participants recruited in 
other phases. Samples were stored, as whole blood or as buffy coat and sera, at -800C for all 
apart from a subset of phase 3 participants whose DNA was extracted from fresh blood and 
stored at -800C.(17) The University of Hong Kong-Hospital Authority Hong Kong West Cluster 
Joint Institutional Review Board approved the study. The Guangzhou Medical Ethics Committee 
of the Chinese Medical Association approved GBCS, including the use of genetic data. All 
participants gave written, informed consent prior to participation.  
 
DNA extraction and SNP analysis 
DNA was extracted using QIAamp DNA Blood Midi Kit (Catalog No.51185) for fresh blood in 
Hong Kong, phenol-chloroform extraction for fresh blood in GBCS and magnetic bead 
extraction for previously stored specimens in GBCS (17). SNPs were selected from genes (ESR1, 
ESR2 and CYP19A1) (18-21) functionally relevant to estradiol or breast cancer, with minor allele 
frequency >5% in Chinese (22). Five SNPs (rs2175898 from ESR1, rs1256030 and rs1256031 
from ESR2, and rs10046 and rs1008805 from CYP19A1) were analyzed at the Centre for 
Genomic Sciences of the University of Hong Kong, for the Hong Kong sample, and a 
commercial company (Beijing Capital Bio Corporation) in Beijing, for the GBCS sample, using 
a Mass ARRAY system (Sequenom, San Diego, California). For DNA quality analysis we used 
spectrophotometry for most of the samples and gel electrophoresis for four duplicate check 
controls and six randomly selected samples in each DNA sample plate. The determined sample 
concentration and A260/280 ratios were 10-20ng/uL and 1.7-2.0, respectively. A call rate <80% 
was considered failure. All SNPs passed with a call rate >95%. 
 
 
Exposure  
The exposure was genetically predicted log 17β-estradiol (pmol/L). 
 
Outcome 
The outcomes were systolic and diastolic blood pressure, LDL-cholesterol, HDL-cholesterol, 
triglycerides, glucose, body mass index, waist hip ratio, waist circumference, and Framingham 
score. The Framingham score overestimates absolute risk of cardiovascular disease in Chinese 
populations (23), but provides a risk ranking. The Framingham score was calculated from age, 
LDL-cholesterol, HDL-cholesterol, systolic blood pressure, diastolic blood pressure, diabetes 
(fasting plasma glucose≥7.0mmol/L, previous diagnosis or use of anti-diabetic medication) but 
excluded smoking to assess cardiovascular disease risk reflected by biological factors which 
provides more mechanistic information and is assessed more precisely. 
 Statistical analysis 
In the sample of young Chinese women from Hong Kong, we established genetic predictors of log 17β-
estradiol based on 2 SNPs from stepwise linear regression starting with 5 SNPs with replication in 1,000 
bootstrapping samples, as described previously (13). In the GBCS sample, we tested for Hardy-Weinberg 
equilibrium at the SNP locus on a contingency table of observed-versus-predicted frequencies with an 
exact test. We used ANOVA to assess whether genetically predicted log 17β-estradiol was associated 
with potential confounders. We used separate sample instrumental variable analysis to estimate the 
association of log 17β-estradiol with cardiovascular risk factors and Framingham score in the sample of 
older Chinese women from GBCS by using suest (seemingly unrelated regression command in Stata) to 
generate the Wald estimates from the ratio of the association of genetic determinants of log 17β-estradiol 
with cardiovascular risk factors and Framingham score in GBCS and the association of genetic 
determinants of log 17β-estradiol with log 17β-estradiol in the sample of young women  (24). Figure 1 
shows the flow chart of the study. 
 
 
Sensitivity analyses 
Given the hypothesis that estrogen may have a different effect depending on cardiovascular 
disease status, we repeated the analyses by restricting the samples without self-reported history 
of cardiovascular diseases (ischemic heart disease, stroke/ transient ischemic attack, angina, 
myocardial infarction, valvular heart disease or peripheral vascular disease). We did not include 
rheumatic heart disease because it has an infectious origin different from other types of 
cardiovascular disease (25). 
 
All statistical analyses were conducted using Stata 13.1 (StataCorp LP, College Station, Texas, 
USA). 
 
Results 
Among the young Chinese woman samples (n=236, one participant was excluded because of an 
invalid 17β-estradiol value). The F statistic for the regression on log 17β-estradiol on genetic 
score was 13.2, with an adjusted R2 of 4.9%, suggesting that the analyses were unlikely to be 
susceptible to weak instrument bias. Among the 22,067 women in all 3 phases of GBCS, SNP 
testing was available for 3,316 women, with availability depending on the phase of recruitment 
and other logistical concerns, but not on cardiovascular risk factors. All the SNPs had a call rate 
>95%. Among these 3,316 women, 3,096 (93.4%) had all selected SNPs. The 2 SNPs used to 
generate the genetic score did not deviate from the Hardy Weinberg equilibrium (p=0.42 for 
rs1008805; and p=0.73 for rs2175898) in the GBCS sample. Table 1 shows genetically predicted 
estrogen was unrelated to age, smoking, alcohol use, physical activity, education and longest 
held occupation among older Southern Chinese women from GBCS. 
 
Table 2 shows the associations of genetically predicted log 17β-estradiol with cardiovascular 
disease risk factors. Genetically predicted log 17β-estradiol was not associated with any of the 
cardiovascular disease risk factors among older Southern Chinese women. Genetically predicted 
17β-estradiol was also not associated with Framingham score with estimates very close to null (-
0.01, 95% confidence interval -1.34 to 1.31). The analyses restricted to those without self-
reported cardiovascular disease produced directionally similar estimates (Table 3).  
 
Discussion 
To date, this is the first study using Mendelian randomization analysis to examine the role of 
estrogen in traditional cardiovascular disease risk factors. Using a study design less susceptible 
to confounding than observational studies which also allows examination of the effect of lifelong 
estrogen exposure, our results are consistent with RCTs of HRT where estrogen did not affect 
systolic and diastolic blood pressure, HDL cholesterol or body mass index (1), suggesting 
exogenous and endogenous estrogen have similar effects, as well as partly validating the 
Mendelian randomization approach. However, we did not show that estrogen reduced LDL 
cholesterol although the direction of the estimate was the same as in RCTs of HRT.(1) The null 
findings for glucose are inconsistent with the improvement in glycemic metabolism and  lower 
waist circumference   seen in RCTs of HRT (26, 27). Lastly, we did not find any association of 
estrogen with predicted risk of future ischemic heart disease events, proxied by Framingham 
score, consistent with the WHI findings in the estrogen alone treatment arm (28).   
 
Although we used a separate sample Mendelian randomization analysis which is less susceptible 
to confounding and allows estimation of the effect of lifelong estrogen exposure, limitations 
existed. First, cardiovascular events are not available, so estrogen could protect against 
cardiovascular events by pathways other than those examined here. Our previous study showed 
estrogen reduced the inflammation implicated in cardiovascular disease (13). Estrogen might 
also reduce testosterone (29), which could be beneficial. However, estrogen also promotes 
thrombosis that can provoke cardiovascular events (30). Second, although a separate sample 
Mendelian randomization analysis may be less susceptible to measurement of the exposure 
compared to a conventional Mendelian randomization analysis, we are unable to assess if the 
instrument violates the exclusion restriction criteria, i.e., that the genetic polymorphisms only 
affected cardiovascular disease risk via estrogen, as we do not have estrogen polymorphisms, 
and estrogen and cardiovascular risk factors were all measured in the same dataset. However, the 
estrogen related genetic polymorphisms are in the sex-steroid pathway, and genetically predicted 
estrogen was unrelated to testosterone in the sample of young women (13). Third, we did not use 
estrogen polymorphisms from genome wide association studies (GWAS), because no such 
studies have reliably identified estrogen related genetic polymorphisms in Chinese women. 
Therefore, we have established our own genetic prediction rule in a young Chinese women 
sample using stepwise regressions and bootstrapping methods, as described previously.(13) 
Fourth, Mendelian randomization analysis may be susceptible to confounding by population 
stratification but the participants from this study had the same genetic origin. Fifth, although our 
study is largely in line with the results from RCTs of HRT but the confidence intervals are wide, 
so we cannot rule out small effects on glucose and LDL cholesterol as seen in RCTs (31). Our 
study was powered to detect a change of 0.23 standard deviation in cardiovascular disease risk 
factors, for example a blood pressure change of 5 mmHg per increase in one log unit change in 
estrogen. As such our study was underpowered to detect small effects of estrogen that could be 
important to population health, although less clinically relevant. Sixth, we used genetic 
determinants of estrogen in young women to avoid reverse causality, however effects of genetic 
determinants could vary with age. Lastly, our study only focused on estrogen and hence our 
result could not directly infer the relation of combined treatment (i.e. estrogen and a progestin) 
on cardiovascular health. Furthermore, this makes comparison of our results with previous RCTs 
of HRT more difficult because not all trials had an estrogen only arm. However, this may also 
imply our study adds to our understanding of the effect of estrogen alone on cardiovascular risk 
factors. 
 
Our study provides an example of a feasible method of implementing Mendelian randomization 
studies cost-effectively when GWAS of uncommonly measured exposures are not available. It 
also confirms a fairly minor role of estrogen in cardiovascular disease risk factors, consistent 
with the minor inflection in cardiovascular disease rates at the menopause (32). Our study does 
not suggest that the effect of estrogen on cardiovascular disease varies by disease status. As such, 
observations concerning differences by timing of HRT initiation (5) might be a false positive to 
which post-hoc analyses are susceptible, and would need confirmation from studies specifically 
designed to examine the timing hypothesis (4). Our findings are not consistent with observational 
studies of HRT, but these are known to be biased by HRT users being of higher socio-economic 
status and more health conscious than non-users (33-35).  Our results might also be relevant to 
the much more common estrogen exposure from the oral contraceptive pill, whose effects on 
cardiovascular events have never been assessed in an RCT (36). Observational studies have 
found combined contraceptive pills (i.e. estrogen and progestin) associated with higher blood 
pressure, LDL cholesterol, higher risk of thrombosis, and lower HDL cholesterol, which could 
be due to the estrogen or progestin or residual confounding (36). However, we cannot assess this 
possibility because we do not have these events, or their biomarkers, such as thrombin. 
 Our study provides new evidence concerning the relation of estrogen with cardiovascular disease 
risk factors using a separate sample Mendelian randomization analysis. No evidence supporting 
potential cardio-protection by estrogen or evidence for the timing hypothesis was found. 
However, given the limitations of this study, a larger Mendelian randomization analysis with 
cardiovascular outcomes may help clarify the role of estrogen in cardiovascular disease in a 
timely manner, with corresponding implications for public health, clinical practice and etiology 
concerning estrogen exposures such as HRT and oral contraceptives. 
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Table 1: Genetically predicted log 17β-estradiol by lifestyle and socio-demographics among 
Southern Chinese women in the Guangzhou Biobank Cohort Study  
Characteristic  Sample size 
Predicted 
log 17β-
estradiol 
(pmol/L) 
ap value 
Age group  50-54 379 4.73 (0.10) 0.24 
 55-59 1061 4.74 (0.10)  
 60-64 696 4.73 (0.10)  
 65-69 538 4.73 (0.10)  
 70-74 289 4.73 (0.09)  
 75-79 94 4.73 (0.10)  
 80+ 38 4.74 (0.09)  
     
Smoking status Never smokers 2,992 4.7 (0.10) 0.44 
 Former smokers 52 4.8 (0.08)  
 Current smokers 45 4.7 (0.10)  
     
Alcohol status Never drinkers 2,157 4.7 (0.10) 0.70 
 Former drinkers 101 4.7 (0.10)  
 Current drinkers 808 4.7 (0.10)  
     bPhysical activity  Inactive 194 4.7 (0.10) 0.75 
(IPAQ) Minimally active 998 4.7 (0.10)  
 HEPA active 1,903 4.7 (0.10)  
     
Education Less than primary 426 4.7 (0.10) 0.26 
 Primary 1,004 4.7 (0.10)  
 Junior middle 746 4.7 (0.10)  
 Senior middle 688 4.7 (0.10)  
 Junior college 154 4.7 (0.09)  
 College 77 4.7 (0.10)  
     cLongest-held  Manual  2,099 4.7 (0.10) 0.72 
occupation Non-manual 638 4.7 (0.10)  
 Others 321 4.7 (0.10)  aP value obtained from ANOVA. 
bHEPA: Health-enhancing physical activity (i.e. vigorous activity at least 3 days a week 
achieving at least 1500 metabolic equivalent (MET) minutes per week or activity on 7 days of 
the week, achieving at least 3000 MET minutes per week (IPAQ: International Physical Activity 
Questionnaire). 
cManual occupations are agricultural worker, factory work or sales and service; non-manual are 
administrator/ manager, professional/technical, military/disciplined. 
Table 2: Effect of genetically predicted log 17β-estradiol on cardiovascular disease risk and its 
risk factors among Southern Chinese women in the Guangzhou Biobank Cohort Study using a 
Mendelian randomization analysis 
Cardiovascular risk factors 
 
Sample size Estimate 95% Confidence Interval 
Systolic blood pressure (mmHg) 3,092 -3.83 -11.8 to 4.78 
 
   
Diastolic blood pressure (mmHg) 3,092 -1.18 -5.11 to 2.76 
 
   
HDL cholesterol (mmol/L) 3,079 -0.02 -0.17 to 0.12 
 
   
LDL cholesterol (mmol/L) 3,074 0.16 -0.12 to 0.44 
 
   
Triglyceride (mmol/L) 3,079 -0.08 -0.44 to 0.28 
    
Fasting glucose (mmol/L) 3,072 0.08 -0.47 to 0.63 
 
   
Body mass index (kg/m2) 3,090 -0.13 -1.35 to 1.08 
    
Waist hip ratio 3,085 -0.003 -0.03 to 0.02 
 
   
Waist circumference (cm) 3,087 -0.59 -3.85 to 2.67 
    
Framingham score 3,071 -0.01 -1.34 to 1.31 
 
  
Table 3: Effect of genetically predicted log 17β-estradiol on cardiovascular disease risk and its 
risk factors among Southern Chinese women in the Guangzhou Biobank Cohort Study restricted 
to those without self reported cardiovascular disease status, using a Mendelian randomization 
analysis 
 Absence of self reported cardiovascular diseases 
Cardiovascular risk factors 
 
Sample 
size Estimate 95% Confidence Interval 
Systolic blood pressure (mmHg) 2,916 -1.84 -9.84 to 6.16 
    
Diastolic blood pressure (mmHg) 2,916 -0.44 -4.44 to 3.56 
    
HDL cholesterol (mmol/L) 2,904 -0.02 -0.17 to 0.12 
    
LDL cholesterol (mmol/L) 2,899 0.17 -0.12 to 0.46 
    
Triglyceride (mmol/L) 2,904 -0.10 -0.47 to 0.27 
    
Fasting glucose (mmol/L) 2,900 -0.02 -0.58 to 0.55 
    
Body mass index (kg/m2) 2,915 -0.02 -1.25 to 1.22 
    
Waist hip ratio 2,910 -0.003 -0.03 to 0.02 
    
Waist circumference (cm) 2,911 -0.48 -3.82 to 2.86 
    
Framingham score 2,896 0.03 -1.33 to 1.39 
 
  
Figure 1: Flow chart of the study. A separate-sample instrumental variable analysis with genetic 
instruments, i.e. Mendelian randomization analysis, was used. See detailed in the Methods 
 
